Abstract:Abstract Background N6-methyladenosine (m6A) RNA methylation plays a critical role in key genetic events for various cancers; yet, how m6A functions within the tumor microenvironment (TME) remains to be elucidated. Methods A total of 65,362 single cells from single-cell RNA-seq data derived from 33 CRC tumor samples were analyzed by nonnegative matrix factorization (NMF) for 23 m6A RNA methylation regulators. CRC and Immunotherapy cohorts from public repository were used to determine the prognosis and immune response of TME clusters. Results The fibroblasts, macrophages, T and B cells were respectively grouped into 4 to 5 subclusters and then classified according to various biological processes and different marker genes. Furthermore, it revealed that the m6A RNA methylation regulators might be significantly related to the clinical and biological features of CRC, as well as the pseudotime trajectories of main TME cell types. Bulk-seq analysis suggested that these m6A-mediated TME cell subclusters had significant prognostic value for CRC patients and distinguished immune response for patients who underwent ICB therapy, especially for the CAFs and macrophages. Notably, CellChat analysis revealed that RNA m6A methylation-associated cell subtypes of TME cells manifested diverse and extensive interaction with tumor epithelial cells. Further analysis showed that ligand-receptor pairs, including MIF − (CD74 + CXCR4), MIF − (CD74 + CD44), MDK–NCL and LGALS9 − CD45, etc. mediated the communication between m6A associated subtypes of TME cells and tumor epithelial cells. Conclusions Taken together, our study firstly revealed the m6A methylation mediated intercellular communication of the tumor microenvironment in the regulation of tumor growth and antitumor immunomodulatory processes.

RNA N6-methyladenosine modification in regulating cancer stem cells and tumor immune microenvironment and its implication for cancer therapy

Interaction Between N6-methyladenosine Modification and the Tumor Microenvironment in Colorectal Cancer

Single-cell N6-methyladenosine Regulator Patterns Guide Intercellular Communication of Tumor Microenvironment That Contribute to Colorectal Cancer Progression and Immunotherapy

N6-methyladenosine Modification: an Important Player in the Tumor Immune Microenvironment.

N6-methyladenosine (m6A) in cancer stem cell: From molecular mechanisms to therapeutic implications

N6-methyladenosine (m6a) As a Regulator of Carcinogenesis and Drug Resistance by Targeting Epithelial-Mesenchymal Transition and Cancer Stem Cells

N6-methyladenosine (m6A)RNAmodification in cancer stem cells

N6-methyladenosine (m6a) RNA Modification in Cancer Stem Cells

The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy

Writers, readers, and erasers RNA modifications and drug resistance in cancer

Emerging roles of m6A RNA modification in cancer therapeutic resistance

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Biological and pharmacological roles of m6A modifications in cancer drug resistance

Role of m6A modifications in immune evasion and immunotherapy

Role of N6-methyladenosine RNA modification in cancer

The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications

N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications

The role of m6A methylation in therapy resistance in cancer

The Roles of M6a RNA Modifiers in Human Cancer

RNA N-6-methyladenosine Enzymes and Resistance of Cancer Cells to Chemotherapy and Radiotherapy.

The Emerging Role of N6-Methyladenosine RNA Methylation as Regulators in Cancer Therapy and Drug Resistance